HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.44M | -3.02M | -4.84M | -5.68M | -6.11M |
| Total Depreciation and Amortization | 5.36M | 5.43M | 5.51M | 5.86M | 5.92M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 670.00K | 799.00K | 835.00K | 1.50M | 664.00K |
| Change in Net Operating Assets | 1.95M | -5.00K | 2.00K | 843.00K | 301.00K |
| Cash from Operations | 3.54M | 3.21M | 1.50M | 2.52M | 778.00K |
| Capital Expenditure | -21.00K | -13.00K | 0.00 | 0.00 | -2.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | -1.50M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 0.00 | 13.25M | -- |
| Cash from Investing | -21.00K | -13.00K | -1.50M | 13.25M | -2.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.10M | -2.65M | -15.10M | -1.61M | -2.22M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -176.00K | 0.00 | 0.00 | -317.00K | -283.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -658.00K | -533.00K |
| Cash from Financing | -3.28M | -2.65M | -15.10M | -2.58M | -3.03M |
| Foreign Exchange rate Adjustments | 35.00K | -622.00K | 120.00K | -117.00K | -251.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 278.00K | -84.00K | -14.98M | 13.07M | -2.51M |